Heather J Dalton1, Nicole D Fleming2, Charlotte C Sun3, Priya Bhosale4, Kathleen M Schmeler5, David M Gershenson6. 1. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: Heatherjdalton@gmail.com. 2. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: Nfleming@mdanderson.org. 3. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: CCSun@mdanderson.org. 4. Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: Priya.Bhosale@mdanderson.org. 5. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: KSchmele@mdanderson.org. 6. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: dgershen@mdanderson.org.
Abstract
OBJECTIVE: The aim of this study was to evaluate the activity of bevacizumab in a cohort of women with recurrent low-grade serous carcinoma of the ovary or peritoneum. METHODS: This single-institution retrospective study assessed all patients at MD Anderson Cancer Center with recurrent low-grade serous ovarian or peritoneal cancer who received bevacizumab from 2007 to 2016. Study endpoints included best response, median progression-free survival, median overall survival, and toxicity. RESULTS: Forty patients received 45 separate "patient-regimens." Most received bevacizumab in combination with chemotherapy. Complete response (CR) was seen in 7.5%, while 40% had partial responses (PR) and 30% achieved stable disease (SD). Disease progression occurred in nine patients (22.5%). Overall response rate (CR+PR) to bevacizumab-containing regimens was 47.5%. Clinical benefit (CR+PR+SD) was seen in 77.5% of patients. Median progression free survival was 10.2months (95% CI 7.9, 12.4). Median overall survival was 34.6months (95% CI 29.5, 39.7). Fifteen patients discontinued bevacizumab related to toxicity. CONCLUSIONS: Bevacizumab, most often in combination with chemotherapy, has activity in recurrent low-grade ovarian cancer and should be considered a treatment option for these patients. Further investigation into the most effective chemotherapeutic agent in combination with bevacizumab is warranted.
OBJECTIVE: The aim of this study was to evaluate the activity of bevacizumab in a cohort of women with recurrent low-grade serous carcinoma of the ovary or peritoneum. METHODS: This single-institution retrospective study assessed all patients at MD Anderson Cancer Center with recurrent low-grade serous ovarian or peritoneal cancer who received bevacizumab from 2007 to 2016. Study endpoints included best response, median progression-free survival, median overall survival, and toxicity. RESULTS: Forty patients received 45 separate "patient-regimens." Most received bevacizumab in combination with chemotherapy. Complete response (CR) was seen in 7.5%, while 40% had partial responses (PR) and 30% achieved stable disease (SD). Disease progression occurred in nine patients (22.5%). Overall response rate (CR+PR) to bevacizumab-containing regimens was 47.5%. Clinical benefit (CR+PR+SD) was seen in 77.5% of patients. Median progression free survival was 10.2months (95% CI 7.9, 12.4). Median overall survival was 34.6months (95% CI 29.5, 39.7). Fifteen patients discontinued bevacizumab related to toxicity. CONCLUSIONS:Bevacizumab, most often in combination with chemotherapy, has activity in recurrent low-grade ovarian cancer and should be considered a treatment option for these patients. Further investigation into the most effective chemotherapeutic agent in combination with bevacizumab is warranted.
Authors: Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: Erin K Crane; Charlotte C Sun; Pedro T Ramirez; Kathleen M Schmeler; Anais Malpica; David M Gershenson Journal: Gynecol Oncol Date: 2014-11-08 Impact factor: 5.482
Authors: David M Gershenson; Diane C Bodurka; Karen H Lu; Lisa C Nathan; Ljiljana Milojevic; Kwong K Wong; Anais Malpica; Charlotte C Sun Journal: J Clin Oncol Date: 2015-07-20 Impact factor: 44.544
Authors: Kathleen M Schmeler; Charlotte C Sun; Diane C Bodurka; Michael T Deavers; Anais Malpica; Robert L Coleman; Pedro T Ramirez; David M Gershenson Journal: Gynecol Oncol Date: 2007-12-26 Impact factor: 5.482
Authors: Agustin A Garcia; Hal Hirte; Gini Fleming; Dongyun Yang; Denice D Tsao-Wei; Lynda Roman; Susan Groshen; Steve Swenson; Frank Markland; David Gandara; Sidney Scudder; Robert Morgan; Helen Chen; Heinz-Josef Lenz; Amit M Oza Journal: J Clin Oncol Date: 2008-01-01 Impact factor: 44.544
Authors: Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky Journal: J Clin Oncol Date: 2007-11-20 Impact factor: 44.544
Authors: Jacek P Grabowski; Philipp Harter; Florian Heitz; Eric Pujade-Lauraine; Alexander Reuss; Gunnar Kristensen; Isabelle Ray-Coquard; Julia Heitz; Alexander Traut; Jacobus Pfisterer; Andreas du Bois Journal: Gynecol Oncol Date: 2016-01-22 Impact factor: 5.482
Authors: Koji Matsuo; Hiroko Machida; Shinya Matsuzaki; Brendan H Grubbs; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson; Jason D Wright Journal: Gynecol Oncol Date: 2020-01-15 Impact factor: 5.482
Authors: Robert C Bast; Ursula A Matulonis; Anil K Sood; Ahmed A Ahmed; Adaobi E Amobi; Frances R Balkwill; Monicka Wielgos-Bonvallet; David D L Bowtell; James D Brenton; Joan S Brugge; Robert L Coleman; Giulio F Draetta; Kai Doberstein; Ronny I Drapkin; Mark A Eckert; Robert P Edwards; Kevin M Elias; Darren Ennis; Andrew Futreal; David M Gershenson; Roger A Greenberg; David G Huntsman; Jennifer Xiao Ye Ji; Elise C Kohn; Claudia Iavarone; Ernst R Lengyel; Douglas A Levine; Christopher J Lord; Zhen Lu; Gordon B Mills; Francesmary Modugno; Brad H Nelson; Kunle Odunsi; Jessica A Pilsworth; Robert K Rottapel; Daniel J Powell; Li Shen; Ie-Ming Shih; David R Spriggs; Josephine Walton; Kaiyang Zhang; Rugang Zhang; Lee Zou Journal: Cancer Date: 2019-03-05 Impact factor: 6.921
Authors: Luigi Carlo Turco; Gabriella Ferrandina; Virginia Vargiu; Serena Cappuccio; Anna Fagotti; Giuseppina Sallustio; Giovanni Scambia; Francesco Cosentino Journal: Ann Transl Med Date: 2020-12
Authors: David M Gershenson; Austin Miller; William E Brady; James Paul; Karen Carty; William Rodgers; David Millan; Robert L Coleman; Kathleen N Moore; Susana Banerjee; Kate Connolly; Angeles Alvarez Secord; David M O'Malley; Oliver Dorigo; Stephanie Gaillard; Hani Gabra; Brian Slomovitz; Parviz Hanjani; John Farley; Michael Churchman; Ailith Ewing; Robert L Hollis; C Simon Herrington; Helen Q Huang; Lari Wenzel; Charlie Gourley Journal: Lancet Date: 2022-02-05 Impact factor: 202.731